SEC Form 4 · accession 0001705905-26-000010
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
M Scot Roberts
Officer — Chief Scientific Officer
Period of report
Jul 31, 2026
Accepted (ET)
Aug 3, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001F2 | Jul 31, 2026 | A | 875 | $2.414 | A | 113,699 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026.
- F2In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026.